Bridging the Funding Gap in Drug Development for Amyotrophic Lateral Sclerosis
- 1 June 2026
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology Clinical Practice
- Vol. 16 (3) , e200623
Abstract
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease with few effective treatments and high clinical trial failure rates. Since 1995, only 3 drugs riluzole, edaravone, and tofersen have gained approval from the Food and Drug Administration, all offering modest benefits. Challenges in ALS drug development include poor translational preclinical models, underpowered early-phase trials, and the high cost of late-stage development. Despite federal initiatives such as the Accelerating Access to Critical Therapies for ALS Act and the ALL ALS Consortium, critical gaps remain in funding large multisite trials and sustaining research networks. Accelerating progress requires strengthening national registries, expanding adaptive trial platforms, integrating existing networks, and adopting innovative funding models such as milestone-based public-private partnerships and reinvestment of licensing revenues. A coordinated, sustainable research and funding ecosystem could transform ALS therapy development and serve as a model for advancing treatments for other rare neurodegenerative and neurogenetic disorders.Keywords
This publication has 11 references indexed in Scilit:
- Long-Term Tofersen in SOD1 Amyotrophic Lateral SclerosisJAMA Neurology, 2026
- Reimagining Care and Research for Amyotrophic Lateral SclerosisJAMA Neurology, 2025
- Priorities and Recommendations to Make ALS a Livable Disease Emanating from the 2024 National Academies of Sciences, Engineering, and Medicine Report Living with ALSAnnals of Neurology, 2024
- Biopharmaceutical pipeline funded by venture capital firms, 2014 to 2024Health Affairs Scholar, 2024
- Access for ALL in ALS: A large‐scale, inclusive, collaborative consortium to unlock the molecular and genetic mechanisms of amyotrophic lateral sclerosisMuscle & Nerve, 2024
- Costs of Drug Development and Research and Development Intensity in the US, 2000-2018JAMA Network Open, 2024
- The Cost of Biotech Innovation: Exploring Research and Development Costs of Cell and Gene TherapiesPharmaceutical Medicine, 2023
- Amyotrophic lateral sclerosis: a neurodegenerative disorder poised for successful therapeutic translationNature Reviews Drug Discovery, 2022
- Amyotrophic Lateral SclerosisNew England Journal of Medicine, 2017
- TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic TargetsNeurotherapeutics, 2015